Solid Biosciences Inc. (SLDB)
NASDAQ: SLDB · Real-Time Price · USD
6.19
-0.32 (-4.92%)
Aug 7, 2025, 4:00 PM - Market closed

Company Description

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.

The company’s lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy.

It also develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases.

In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid.

The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Solid Biosciences Inc.
Solid Biosciences logo
CountryUnited States
Founded2013
IPO DateJan 26, 2018
IndustryBiotechnology
SectorHealthcare
Employees100
CEOAlexander Cumbo

Contact Details

Address:
500 Rutherford Avenue, Third Floor
Charlestown, Massachusetts 02129
United States
Phone617 337 4680
Websitesolidbio.com

Stock Details

Ticker SymbolSLDB
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001707502
CUSIP Number83422E105
ISIN NumberUS83422E2046
Employer ID90-0943402
SIC Code2836

Key Executives

NamePosition
Ilan GanotCo-founder, Strategic Advisor to the Chief Executive Officer and Director
Alexander G. CumboPresident, Chief Executive Officer and Director
Ian F. Smith A.C.A., C.P.A.Executive Chair
David Tyronne Howton Jr., J.D.Chief Operating Officer and Secretary
Dr. Gabriel Brooks M.D.Chief Medical Officer
Annie GanotCo-Founder and Vice President of Patient Advocacy
Kevin Tan C.F.A.Chief Financial Officer and Treasurer
Paul HerzichChief Technology Officer
Nicole AndersonDirector of Investor Relations and Corporate Communications
Allison Bogosian J.D.Senior Vice President of Human Resources

Latest SEC Filings

DateTypeTitle
Jul 17, 2025SCHEDULE 13GFiling
Jun 13, 20258-KCurrent Report
Jun 13, 2025S-8Securities to be offered to employees in employee benefit plans
May 27, 2025EFFECTNotice of Effectiveness
May 21, 2025UPLOADFiling
May 15, 20258-KCurrent Report
May 15, 2025424B5Filing
May 15, 2025S-3Registration statement under Securities Act of 1933
May 15, 2025SCHEDULE 13G/AFiling
May 15, 202510-QQuarterly Report